Evidence map›Paper›PMID 40944768›Full record

ArticleCancer immunology, immunotherapy : CII2025

GARP-expressing Tregs as a source of immunosuppressive TGF-β1 in human tumors.

Pierre Van Meerbeeck, Douae Maatougui, Grégoire de Streel, Noora Vaherto, Etienne Marbaix, Frank Aboubakar Nana, Marc Van den Eynde, Alix Devaux, Javier Carrasco, Agnès Noel and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Pierre Van Meerbeeckde Duve Institute, UCLouvain, Brussels, Belgium.
Douae Maatouguide Duve Institute, UCLouvain, Brussels, Belgium.
Grégoire de Streelde Duve Institute, UCLouvain, Brussels, Belgium.
Noora Vahertode Duve Institute, UCLouvain, Brussels, Belgium.
Etienne MarbaixDepartment of Pathology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Frank Aboubakar Nanade Duve Institute, UCLouvain, Brussels, Belgium.
Marc Van den EyndeInstitut de Recherche Clinique Et Expérimentale (Pole MIRO), UCLouvain, Brussels, Belgium.
Alix DevauxGrand Hôpital de Charleroi, Charleroi, Belgium.
Javier CarrascoGrand Hôpital de Charleroi, Charleroi, Belgium.
Agnès NoelLaboratory of Tumor and Development Biology, GIGA, ULiège, Liège, Belgium.
Nicolas van Barende Duve Institute, UCLouvain, Brussels, Belgium. nicolas.vanbaren@uclouvain.be.
Sophie Lucasde Duve Institute, UCLouvain, Brussels, Belgium. sophie.lucas@uclouvain.be.

Funding

FNRS Postdoctoral ResearcherFonds De La Recherche Scientifique - FNRS PDR-TLV#40007289Fonds De La Recherche Scientifique - FNRS PDR-TLV#40007447WEL Research Institute, WELBIO Department CR-2019A-02 and CR-2019A-02 R
6 · The paper itself

Abstract

Most cells produce latent transforming growth factor-beta 1 (TGF-β1), but only very few activate the cytokine via cell type-specific mechanisms. TGF-β1 favors cancer progression by suppressing anti-tumor T cell responses. Which cells produce this immunosuppressive TGF-β1 in human tumors is unknown. Putative sources include cells expressing the glycoprotein A repetitions predominant (GARP) protein, comprising mostly activated regulatory T cells (Tregs) (GARP

Indexed as

NeoplasmsT-Lymphocytes, RegulatoryTransforming Growth Factor beta1FemaleForkhead Transcription FactorsHumansImmune ToleranceLymphocytes, Tumor-InfiltratingMembrane ProteinsSmad2 ProteinForkhead Transcription FactorsLRRC32 protein, humanMembrane ProteinsSmad2 ProteinSMAD2 protein, humanTGFB1 protein, humanTransforming Growth Factor beta1GARPImmunosuppressionQuantitative multiplexed immunohistofluorescenceRegulatory T cellTGF-β1Tumor infiltrating lymphocyte

Identifiers

PMID40944768
PMCPMC12433403

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.